Aenitis, a pioneer in acoustic-based cell manipulation, revolutionizes bioproduction with its non-invasive, scalable acoustofluidic technology, enabling precise, sterile, and cost-effective cell processing for research, clinical, and industrial applications.
At Aenitis, we understand the critical importance of precision and efficiency when it comes to cell handling in research, clinical and manufacturing environment.
We have developed a sole-in-class platform based on acoustic levitation in flow that enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing tens of milliliters per minute to be handled. This patented technology uses acoustic waves to levitate cells without physical contact, minimizing mechanical stress and preserving cell viability and functionality. This high-precision approach enhances yields, reduces costs, and improves cell quality, advancing the fields of cell and gene therapy and biomanufacturing.
Mitis™, our flagship product, is already used for a wide range of applications, including cell sorting, isolation, concentration & washing, from research to clinical and industrial scale.
By precisely controlling levitated cells with sound waves, our system handles cells in full sterile conditions and radically increase productivity while preserving the native state of cells at every step of the engineering process. Today, for example, Aenitis’ approach enables a 15% increase in platelet recovery and a 20% reduction in processing time compared to current standards. It also minimizes handling, reduces costs and prevents platelet activation through acoustic treatment, thereby maintaining optimal quality.
is the Global cell therapy technologies market
expected by 2028 according to (MarketsAndMarkets)
Growing at a CAGR of 29%
As the industry faces a growing demand for scalable and cost-effective solutions, Aenitis is set to address these challenges with its groundbreaking technology. A spin-off from the CNRS (the National Center for Scientific Research) and ESPCI (ParisTech research engineer’s school) Paris, co-founded by Emmanuel Vincent, Mauricio Hoyos and Jean-Luc Aider, the company has developed a platform based on acoustic levitation in flow that enables gentle, non-invasive manipulation of cells at the millifluidic scale, allowing tens of milliliters per minute to be handled.
Our team of experts share a deep passion for advancing the quality of cell processing through innovative biotechnology solutions. Meet the people driving our success.
Emmanuel Vincent, our CEO, will be attending the JP Morgan 43rd Annual Healthcare Conference in San Francisco, CA, USA, from 13 to 16 January. Aenitis,
We are pleased to share that Aenitis has been featured in Biotech et Finances! Our CEO, Emmanuel Vincent, spoke with Guillaume Mollaret about our recent
We are delighted to announce that Aenitis has been featured in Les Echos following our successful fundraising to redefine bioproduction with our sole-in-class acoustofluidic technology!Thanks
Access the full Press Release: English Version / French Version ● Aenitis is set to transform the bioproduction industry by addressing theincreasing need for scalable,
